p53的翻译后修饰及其与砷中毒致人体多器官损伤关系的研究进展

doi:10.3969/j.issn.1004-616x.2021.02.013

摘要/Abstract

摘要： p53是迄今为止备受关注的肿瘤抑制因子之一，与人类肿瘤进展密切相关，其翻译后修饰在细胞周期阻滞、DNA修复、氧化应激、自噬、衰老及凋亡等信号转导途径中发挥重要的调控作用。砷作为一种环境毒物，人体长期暴露于砷污染的环境可致皮肤、肝、肾、肺等多器官损伤，研究表明，p53参与了砷中毒致人体多器官损伤的发生发展，而p53在砷中毒致人体多器官损伤中发挥的调控作用与其翻译后修饰有着紧密联系。因此，本文对p53的翻译后修饰及其与砷中毒致人体多器官损伤的关系进行综述，为深入了解p53在砷中毒致人体多器官损伤中的作用和作为潜在治疗靶点的应用提供参考。

关键词: p53, 翻译后修饰, 砷中毒, 多器官损伤

中图分类号:

R599.9

刘春燕, 张爱华. p53的翻译后修饰及其与砷中毒致人体多器官损伤关系的研究进展[J]. 癌变·畸变·突变, 2021, 33(2): 157-160.

参考文献

[1] HUANG J. Current developments of targeting the p53 signaling pathway for cancer treatment[J]. Pharmacol Ther, 2021, 220:107720.
[2] LIU Y, TAVANA O, GU W. p53 modifications:exquisite decorations of the powerful guardian[J]. J Mol Cell Biol, 2019, 11(7):564-577.
[3] 安冬. 重视燃煤污染型地方性砷中毒的防治管理[J]. 中华地方病学杂志, 2015, 34(1):1-2.
[4] WEN W H, LU L, HE Y F, et al. LincRNAs and base modifications of p53 induced by arsenic methylation in workers[J]. Chem Biol Interact, 2016, 246:1-10.
[5] LIU Y Q, TAVANA O, GU W. p53 modifications:exquisite decorations of the powerful guardian[J]. J Mol Cell Biol, 2019, 11(7):564-577.
[6] WANG S M, ZHAO Y J, AGUILAR A, et al. Targeting the MDM2-p53 protein-protein interaction for new cancer therapy:progress and challenges[J]. Cold Spring Harb Perspect Med, 2017, 7(5):a026245.
[7] WU D Y, PRIVES C. Relevance of the p53-MDM2 axis to aging[J]. Cell Death Differ, 2018, 25(1):169-179.
[8] ZHOU Z, JI Z, WANG Y, et al. TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53[J]. Gastroenterology, 2014, 147(5):1043-1054.
[9] SHEN J J, LI P Y, SHAO X J, et al. The E3 ligase RING1 targets p53 for degradation and promotes cancer cell proliferation and survival[J]. Cancer Res, 2018, 78(2):359-371.
[10] KRUSE J P, GU W. MSL2 promotes Mdm2-independent cytoplasmic localization of p53[J]. J Biol Chem, 2009, 284(5):3250-3263.
[11] SLUSS H K, ARMATA H, GALLANT J, et al. Phosphorylation of serine 18 regulates distinct p53 functions in mice[J]. Mol Cell Biol, 2004, 24(3):976-984.
[12] MACPHERSON D, KIM J, KIM T, et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23[J]. EMBO J, 2004, 23(18):3689-3699.
[13] KAWARADA Y, INOUE Y, KAWASAKI F, et al. TGF-β induces p53/Smads complex formation in the PAI-1 promoter to activate transcription[J]. Sci Rep, 2016, 6:35483.
[14] LAPRESA R, AGULLA J, SÁNCHEZ-MORÁN I, et al. Amyloid-ß promotes neurotoxicity by Cdk5-induced p53 stabilization[J]. Neuropharmacology, 2019, 146:19-27.
[15] LEE E W, OH W, SONG H P, et al. Phosphorylation of p53 at threonine 155 is required for Jab1-mediated nuclear export of p53[J]. BMB Rep, 2017, 50(7):373-378.
[16] CRAIG A L, CHRYSTAL J A, FRASER J A, et al. The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members[J]. Mol Cell Biol, 2007, 27(9):3542-3555.
[17] DEMIR Ö, BARROS E P, OFFUTT T L, et al. An integrated view of p53 dynamics, function, and reactivation[J]. Curr Opin Struct Biol, 2021, 67:187-194.
[18] REED S M, QUELLE D E. p53 acetylation:regulation and consequences[J]. Cancers (Basel), 2014, 7(1):30-69.
[19] WANG D L, KON N, LASSO G, et al. Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode[J]. Nature, 2016, 538(7623):118-122.
[20] CHEN S, KAPILASHRAMI K, SENEVIRATHNE C, et al. Substrate-differentiated transition states of SET7/9-catalyzed lysine methylation[J]. J Am Chem Soc, 2019, 141(20):8064-8067.
[21] VESCHI V, LIU Z H, VOSS T C, et al. Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy for p53 activation in high-risk neuroblastoma[J]. Cancer Cell, 2017, 31(1):50-63.
[22] CHANDRAMOULI B, MELINO G, CHILLEMI G. Smyd2 conformational changes in response to p53 binding:role of the C-terminal domain[J]. Mol Oncol, 2019, 13(6):1450-1461.
[23] CUI G F, PARK S, BADEAUX A I, et al. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53[J]. Nat Struct Mol Biol, 2012, 19(9):916-924.
[24] HWANG J W, KIM S N, MYUNG N, et al. PRMT5 promotes DNA repair through methylation of 53BP1 and is regulated by Src-mediated phosphorylation[J]. Commun Biol, 2020, 3(1):428.
[25] CHAO C, HERR D, CHUN J, et al. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression[J]. EMBO J, 2006, 25(11):2615-2622.
[26] LI H M, BI Y R, LI Y, et al. A potent CBP/p300-Snail interaction inhibitor suppresses tumor growth and metastasis in wild-type p53-expressing cancer[J]. Sci Adv, 2020, 6(17):eaaw8500.
[27] RODIER G, KIRSH O, BARAIBAR M, et al. The transcription factor E4F1 coordinates CHK1-dependent checkpoint and mitochondrial functions[J]. Cell Rep, 2015, 11(2):220-233.
[28] LIU X, TAN Y, ZHANG C, et al. NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2[J]. EMBO Rep, 2016, 17(3):349-366.
[29] ZHAO T, SUN D, ZHAO M, et al. N6-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation[J]. Environ Pollut, 2020, 259:113908.
[30] LI Y, JIANG R, ZHAO Y, et al. Opposed arsenite-mediated regulation of p53-survivin is involved in neoplastic transformation, DNA damage, or apoptosis in human keratinocytes[J]. Toxicology, 2012, 300(3):121-131.
[31] HUANG Y L, ZHANG J L, MCHENRY K T, et al. Induction of cytoplasmic accumulation of p53:a mechanism for low levels of arsenic exposure to predispose cells for malignant transformation[J]. Cancer Res, 2008, 68(22):9131-9136.
[32] YANG Y, LIU C Y, XIE T T, et al. Role of inhibiting Chk1-p53 pathway in hepatotoxicity caused by chronic arsenic exposure from coal-burning[J/OL]. Hum Exp Toxicol, 2021. DOI:10.1177/096032712098888.
[33] LI Y, ZHAO Y, JIANG R R, et al. DNA-PKcs-mediated stabilization of p53 by JNK2 is involved in arsenite-induced DNA damage and apoptosis in human embryo lung fibroblast cells[J]. Toxicol Lett, 2012, 210(3):302-310.
[34] CHEN S, WU J L, LIANG Y, et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site[J]. Cancer Cell, 2021, 39(2):225-239.e8.
[35] 张爱华, 潘雪莉, 夏玉洁, 等. p53基因甲基化和突变与燃煤污染型砷中毒关系研究[J]. 中华预防医学杂志, 2011, 45(5):393-398.
[36] ZHANG A H, FENG H, YANG G H, et al. Unventilated indoor coal-fired stoves in Guizhou Province, China:cellular and genetic damage in villagers exposed to arsenic in food and air[J]. Environ Health Perspect, 2007, 115(4):653-658.
[37] DE CHAUDHURI S, KUNDU M, BANERJEE M, et al. Arsenic-induced health effects and genetic damage in keratotic individuals:involvement of p53 arginine variant and chromosomal aberrations in arsenic susceptibility[J]. Mutat Res, 2008, 659(1/2):118-125.
[38] MULLARD A. p53 programmes plough on[J]. Nat Rev Drug Discov, 2020, 19(8):497-500.
[39] 张爱华, 曾奇兵. 新形势下地方性砷中毒科学防治的新机遇与挑战[J]. 中华地方病学杂志, 2019, 38(2):87-90.
[40] XIA S Q, SUN Q, ZOU Z L, et al. Ginkgo biloba extract attenuates the disruption of pro-and anti-inflammatory T-cell balance in peripheral blood of arsenicosis patients[J]. Int J Biol Sci, 2020, 16(3):483-494.
[41] CHEN X, WANG D P, SUN B F, et al. GBE attenuates arsenite-induced hepatotoxicity by regulating E2F1-autophagy-E2F7a pathway and restoring lysosomal activity[J]. J Cell Physiol, 2021, 236(5):4050-4065.
[42] BAHRAMI A, SATHYAPALAN T, MOALLEM S A, et al. Counteracting arsenic toxicity:Curcumin to the rescue?[J]. J Hazard Mater, 2020, 400:123160.